IMO Paxalisib's unique dual PI3K/mTOR pathway inhibitors, should...

IMO Paxalisib's unique dual PI3K/mTOR pathway inhibitors, should benefit future brain cancer patients who receive a testing program of the genetic makeup of the tumours, which leads to the suggested treatments.
The future of childhood cancer treatment
Associate Professor Ziegler said the focus of the ZERO program was showing it was possible to do the genetic testing and get results back quickly enough to be able to make a difference for each child.
But they had not been able to see whether the children had been able to access the recommended drugs.
As well as improving access to new cancer treatments, the researchers also want to look at combining treatments to attack the cancer, as well as expand the program to include children with less aggressive tumours.
Dr Anthony Joshua, Associate Professor of Oncology at the Kinghorn Cancer Centre and UNSW, said this "world class" program was at the cutting edge of cancer treatment for children.
"It's the foundation of what's going to come in the next 50 years, so this is the way we're going to advance cancer care both adults and kids," he said.

disallowed/national/thomas-had-a-rare-brain-cancer-and-no-good-options-then-he-joined-a-clinical-trial-20201005-p5625k.html

Very exciting times ahead in the next two years.

Regards.